GlassScriptPhysician profile
James David Spearman
NPI 1699704213
$1,168.90
in general payments reported to CMS, 2019-2025
13 companies · $21.39 in 2025
The $21.39 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.05 · 2020: $86.56 · 2021: $13.27 · 2022: $251 · 2023: $772 · 2024: $13.39 · 2025: $21.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601 · Travel and Lodging: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.31 |
| Travel and Lodging | $205.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Peerless Surgical INC. | $318.21 | 2023 | |
| Depuy Synthes Sales INC. | $211.38 | 2022-2023 | Dynacord |
| Anika Therapeutics, INC. | $144.45 | 2022 | |
| Skeletal Dynamics INC | $129.98 | 2023 | Align, Implate, Geminus |
| Avanos Medical | $123.69 | 2023 | On-Q* Pump and Accessories |
| Orthalign INC | $75.13 | 2020 | |
| Abbott Laboratories | $60.99 | 2021-2023 | Axium, Penta |
| Horizon Therapeutics Plc | $27.61 | 2023 | Krystexxa |
| Ferring Pharmaceuticals INC. | $21.39 | 2025 | Euflexxa |
| Heron Therapeutics, INC. | $20.20 | 2023 | Zynrelef |
| Medline Industries LP | $13.39 | 2024 | |
| Zyla Life Sciences, INC. | $11.43 | 2020 | |
| Medtronic USA, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Spearman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.